Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome

Current Opinion in Pharmacology

Volumn 20, Issue , 2015, Pages 124-134

  Scharf, Sebastian H ^a   Jaeschke, Georg ^a   Wettstein, Joseph G ^a   Lindemann, Lothar ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 6 METHYL 2 PHENYLAZO 3 PYRIDINOL; AMFEBUTAMONE; ARIPIPRAZOLE; BASIMGLURANT; BENZODIAZEPINE; CARBAMAZEPINE; CITALOPRAM; CLONIDINE; DEXAMPHETAMINE; DIPRAGLURANT; ESCITALOPRAM; FENOBAM; FLUOXETINE; FRAGILE X MENTAL RETARDATION PROTEIN; GUANFACINE; LAMOTRIGINE; MAVOGLURANT; MELATONIN; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; METHYLPHENIDATE; QUETIAPINE; RISPERIDONE; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; 2-CHLORO-4-(1-(4-FLUOROPHENYL)-2,5-DIMETHYL-1H-IMIDAZOL-4-YLETHYNYL)PYRIDINE; AMINO ACID RECEPTOR BLOCKING AGENT; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ALLELE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DEPRESSION; DNA METHYLATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DYSKINESIA; FMR1 GENE; FRAGILE X SYNDROME; GENE; GENE FUNCTION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; HUMAN; LONG TERM POTENTIATION; MOLECULAR PATHOLOGY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; KNOCKOUT MOUSE; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOPHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; FRAGILE X SYNDROME; HUMANS; IMIDAZOLES; INDOLES; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; PHENOTYPE; PYRIDINES; RECEPTOR, METABOTROPIC GLUTAMATE 5;

EID: 84922589070     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.11.004     Document Type: Review

References (83)

1. J.N. Kew, and J.A. Kemp Ionotropic and metabotropic glutamate receptor structure and pharmacology Psychopharmacology (Berl) 179 2005 4 29
2. C.J. Swanson, M. Bures, M.P. Johnson, A.M. Linden, J.A. Monn, and D.D. Schoepp Metabotropic glutamate receptors as novel targets for anxiety and stress disorders Nat Rev Drug Discov 4 2005 131 144
3. D.D. Schoepp, D.E. Jane, and J.A. Monn Pharmacological agents acting at subtypes of metabotropic glutamate receptors Neuropharmacology 38 1999 1431 1476
4. F.M. Ribeiro, M. Paquet, S.P. Cregan, and S.S. Ferguson Group I metabotropic glutamate receptor signalling and its implication in neurological disease CNS Neurol Disord Drug Targets 9 2010 574 595
5. C.M. Niswender, and P.J. Conn Metabotropic glutamate receptors: physiology, pharmacology, and disease Annu Rev Pharmacol Toxicol 50 2010 295 322
6. R. Shigemoto, and N. Mizuno Metabotropic glutamate receptors - immunocytochemical and in situ hybridization analyses O. Ottersen, J. Storm-Mathisen, Handbook of Chemical Neuroanatomy: Glutamate 2000 Elsevier 63 98
7. Z. Nusser, E. Mulvihill, P. Streit, and P. Somogyi Subsynaptic segregation of metabotropic and ionotropic glutamate receptors as revealed by immunogold localization Neuroscience 61 1994 421 427
8. R. Lujan, J.D. Roberts, R. Shigemoto, H. Ohishi, and P. Somogyi Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites J Chem Neuroanat 13 1997 219 241
9. D.F. Condorelli, F. Conti, V. Gallo, F. Kirchhoff, G. Seifert, C. Steinhauser, A. Verkhratsky, and X. Yuan Expression and functional analysis of glutamate receptors in glial cells Adv Exp Med Biol 468 1999 49 67
10. A.J. Verkerk, M. Pieretti, J.S. Sutcliffe, Y.H. Fu, D.P. Kuhl, A. Pizzuti, O. Reiner, S. Richards, M.F. Victoria, and F.P. Zhang Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome Cell 65 1991 905 914
11. O. Penagarikano, J.G. Mulle, and S.T. Warren The pathophysiology of fragile x syndrome Annu Rev Genomics Hum Genet 8 2007 109 129
12. E.W. Khandjian, F. Corbin, S. Woerly, and F. Rousseau The fragile X mental retardation protein is associated with ribosomes Nat Genet 12 1996 91 93
13. B. Laggerbauer, D. Ostareck, E.M. Keidel, A. Ostareck-Lederer, and U. Fischer Evidence that fragile X mental retardation protein is a negative regulator of translation Hum Mol Genet 10 2001 329 338
14. J.C. Darnell, S.J. Van Driesche, C. Zhang, K.Y. Hung, A. Mele, C.E. Fraser, E.F. Stone, C. Chen, J.J. Fak, and S.W. Chi FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism Cell 146 2011 247 261
15. The Dutch-Belgian Fragile X Consortium Fmr1 knockout mice: a model to study fragile X mental retardation Cell 78 1994 23 33
16. R.F. Kooy Of mice and the fragile X syndrome Trends Genet 19 2003 148 154
17. R.J. Hagerman, V. Des-Portes, F. Gasparini, S. Jacquemont, and B. Gomez-Mancilla Translating molecular advances in fragile X syndrome into therapy: a review J Clin Psychiatry 75 2014 e294 e307
18. K.M. Huber, S.M. Gallagher, S.T. Warren, and M.F. Bear Altered synaptic plasticity in a mouse model of fragile X mental retardation Proc Natl Acad Sci U S A 99 2002 7746 7750
19. I.J. Weiler, S.A. Irwin, A.Y. Klintsova, C.M. Spencer, A.D. Brazelton, K. Miyashiro, T.A. Comery, B. Patel, J. Eberwine, and W.T. Greenough Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation Proc Natl Acad Sci U S A 94 1997 5395 5400
20. M.F. Bear, K.M. Huber, and S.T. Warren The mGluR theory of fragile X mental retardation Trends Neurosci 27 2004 370 377
21. A.L. Bhakar, G. Dolen, and M.F. Bear The pathophysiology of fragile X (and what it teaches us about synapses) Annu Rev Neurosci 35 2012 417 443
22. D.D. Krueger, and M.F. Bear Toward fulfilling the promise of molecular medicine in fragile X syndrome Annu Rev Med 62 2011 411 429
23. G. Dölen, E. Osterweil, B.S. Rao, G.B. Smith, B.D. Auerbach, S. Chattarji, and M.F. Bear Correction of fragile X syndrome in mice Neuron 56 2007 955 962
24. L. Lindemann, G. Jaeschke, A. Michalon, E. Vieira, M. Honer, W. Spooren, R. Porter, T. Hartung, S. Kolczewski, and B. Buttelmann CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor J Pharmacol Exp Ther 339 2011 474 486
25. A. Michalon, M. Sidorov, T.M. Ballard, L. Ozmen, W. Spooren, J.G. Wettstein, G. Jaeschke, M.F. Bear, and L. Lindemann Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice Neuron 74 2012 49 56
26. R.J. Hagerman, E. Berry-Kravis, W.E. Kaufmann, M.Y. Ono, N. Tartaglia, A. Lachiewicz, R. Kronk, C. Delahunty, D. Hessl, and J. Visootsak Advances in the treatment of fragile X syndrome Pediatrics 123 2009 378 390
27. W. Chonchaiya, A. Schneider, and R.J. Hagerman Fragile X: a family of disorders Adv Pediatr 56 2009 165 186
28. M. Handt, A. Epplen, S. Hoffjan, K. Mese, J.T. Epplen, and G. Dekomien Point mutation frequency in the FMR1 gene as revealed by fragile X syndrome screening Mol Cell Probes 28 2014 279 283
29. R. Hagerman, and P. Hagerman Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome Lancet Neurol 12 2013 786 798
30. D. Loesch, and R. Hagerman Unstable mutations in the FMR1 gene and the phenotypes Adv Exp Med Biol 769 2012 78 114
31. D.Z. Loesch, R.M. Huggins, and R.J. Hagerman Phenotypic variation and FMRP levels in fragile X Ment Retard Dev Disabil Res Rev 10 2004 31 41
32. D.I. Pretto, G. Mendoza-Morales, J. Lo, R. Cao, A. Hadd, G.J. Latham, B. Durbin-Johnson, R. Hagerman, and F. Tassone CGG allele size somatic mosaicism and methylation in FMR1 premutation alleles J Med Genet 51 2014 309 318
33. F. Tassone, R.J. Hagerman, L.W. Gane, and A.K. Taylor Strong similarities of the FMR1 mutation in multiple tissues: postmortem studies of a male with a full mutation and a male carrier of a premutation Am J Med Genet 84 1999 240 244
34. D. Pretto, C.M. Yrigollen, H.T. Tang, J. Williamson, G. Espinal, C.K. Iwahashi, B. Durbin-Johnson, R.J. Hagerman, P.J. Hagerman, and F. Tassone Clinical and molecular implications of mosaicism in FMR1 full mutations Front Genet 5 2014 318
35. F. Rousseau, D. Heitz, J. Tarleton, J. MacPherson, H. Malmgren, N. Dahl, A. Barnicoat, C. Mathew, E. Mornet, and I. Tejada A multicenter study on genotype-phenotype correlations in the fragile X syndrome, using direct diagnosis with probe StB12.3: the first 2,253 cases Am J Hum Genet 55 1994 225 237
36. R.A. Kumar, and S.L. Christian Genetics of autism spectrum disorders Curr Neurol Neurosci Rep 9 2009 188 197
37. E. Berry-Kravis Epilepsy in fragile X syndrome Dev Med Child Neurol 44 2002 724 728
38. P.J. Hagerman, and C.E. Stafstrom Origins of epilepsy in fragile x syndrome Epilepsy Curr/Am Epilepsy Soc 9 2009 108 112
39. S.A. Kidd, A. Lachiewicz, D. Barbouth, R.K. Blitz, C. Delahunty, D. McBrien, J. Visootsak, and E. Berry-Kravis Fragile X syndrome: a review of associated medical problems Pediatrics 134 2014 995 1005
40. E. Berry-Kravis, A. Sumis, C. Hervey, and S. Mathur Clinic-based retrospective analysis of psychopharmacology for behavior in fragile x syndrome Int J Pediatr 2012 2012 843016
41. S.S. Hall, A.A. Lightbody, and A.L. Reiss Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome Am J Ment Retard 113 2008 44 53
42. L.V. Gabis, Y.K. Baruch, A. Jokel, and R. Raz Psychiatric and autistic comorbidity in fragile X syndrome across ages J Child Neurol 26 2011 940 948
43. S.W. Harris, D. Hessl, B. Goodlin-Jones, J. Ferranti, S. Bacalman, I. Barbato, F. Tassone, P.J. Hagerman, H. Herman, and R.J. Hagerman Autism profiles of males with fragile X syndrome Am J Ment Retard 113 2008 427 438
44. T.T. Heard, S. Ramgopal, J. Picker, S.A. Lincoln, A. Rotenberg, and S.V. Kothare EEG abnormalities and seizures in genetically diagnosed Fragile X syndrome Int J Dev Neurosci 38 2014 155 160
45. R. Kronk, E.E. Bishop, M. Raspa, J.O. Bickel, D.A. Mandel, and D.B. Bailey Jr. Prevalence, nature, and correlates of sleep problems among children with fragile X syndrome based on a large scale parent survey Sleep 33 2010 679 687
46. Medications for Individuals with Fragile X Syndrome (Oct 2012): The fragile X clinical & research consortium, (2012). http://www.fragilex.org/wp-content/uploads/2012/08/Medications-for-Individuals-with-Fragile-X-Syndrome2012-Oct.pdf.
47. A.S. Dore, K. Okrasa, J.C. Patel, M. Serrano-Vega, K. Bennett, R.M. Cooke, J.C. Errey, A. Jazayeri, S. Khan, and B. Tehan Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain Nature 511 2014 557 562
48. J.C. Pecknold, D.J. McClure, L. Appeltauer, L. Wrzesinski, and T. Allan Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study J Clin Psychopharmacol 2 1982 129 133
49. J.B. Patel, C. Martin, and J.B. Malick Differential antagonism of the anticonflict effects of typical and atypical anxiolytics Eur J Pharmacol 86 1982 295 298
50. R.H. Porter, G. Jaeschke, W. Spooren, T.M. Ballard, B. Buttelmann, S. Kolczewski, J.U. Peters, E. Prinssen, J. Wichmann, and E. Vieira Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity J Pharmacol Exp Ther 315 2005 711 721
51. C.T.H. Friedmann, L.J. Davis, P.E. Ciccone, and R.T. Rubin Phase-II double-blind controlled-study of a new anxiolytic, fenobam (Mcn-3377) vs placebo Curr Ther Res Clin E 27 1980 144 151
52. E. Berry-Kravis, D. Hessl, S. Coffey, C. Hervey, A. Schneider, J. Yuhas, J. Hutchison, M. Snape, M. Tranfaglia, D.V. Nguyen, and R. Hagerman A pilot open label, single dose trial of fenobam in adults with fragile X syndrome J Med Genet 46 2009 266 271
53. M.A. Varney, N.D. Cosford, C. Jachec, S.P. Rao, A. Sacaan, F.F. Lin, L. Bleicher, E.M. Santori, P.J. Flor, and H. Allgeier SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5 J Pharmacol Exp Ther 290 1999 170 181
54. F. Gasparini, K. Lingenhohl, N. Stoehr, P.J. Flor, M. Heinrich, I. Vranesic, M. Biollaz, H. Allgeier, R. Heckendorn, and S. Urwyler 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist Neuropharmacology 38 1999 1493 1503
55. G. Jaeschke, J.G. Wettstein, R.E. Nordquist, and W. Spooren mGlu5 receptor antagonists and their therapeutic potential Expert Opin Ther Pat 18 2008 123 142
56. K.A. Emmitte mGlu5 negative allosteric modulators: a patent review (2010-2012) Expert Opin Ther Pat 23 2013 393 408
57. L. Lindemann, G. Jaeschke, R.H. Porter, S. Scharf, B. Kuennecke, M. von Kienlin, A. Harrison, A. Paehler, C. Funk, and A. Gloge Preclinical pharmacological profile of basimglurant (RO4917523, RG7090), a unique mGlu5 negative allosteric modulator in clinical development for both Fragile X syndrome and depression Curr Neuropharmacol 12 2014 35
58. G. Jaeschke, S. Kolczewski, E. Vieira, B. Büttelmann, J. Huwyler, J.-U. Peters, E. Prinssen, A. Ricci, D. Rueher, and M. Schneider Discovery of the mGlu5 negative allosteric modulator basimglurant (RO4917523) Curr Neuropharmacol 12 2014 28
59. I. Vranesic, S. Ofner, P.J. Flor, G. Bilbe, R. Bouhelal, A. Enz, S. Desrayaud, K. McAllister, R. Kuhn, and Gasparini F: AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: Identification, SAR and pharmacological characterization Bioorg Med Chem 22 2014 5790 5803
60. E. Bezard, E.Y. Pioli, Q. Li, F. Girard, V. Mutel, C. Keywood, F. Tison, O. Rascol, and S.M. Poli The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model Mov Disord 29 2014 1074 1079
61. E. Chae, Y.J. Shin, E.J. Ryu, M.K. Ji, N. Ryune Cho, K.H. Lee, H.J. Jeong, S.J. Kim, Y. Choi, and K. Seok Oh Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators Bioorg Med Chem Lett 23 2013 2134 2139
62. M. Walles, T. Wolf, Y. Jin, M. Ritzau, L.A. Leuthold, J. Krauser, H.P. Gschwind, D. Carcache, M. Kittelmann, and M. Ocwieja Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects Drug Metab Dispos 41 2013 1626 1641
63. S. Jacquemont, A. Curie, V. des Portes, M.G. Torrioli, E. Berry-Kravis, R.J. Hagerman, F.J. Ramos, K. Cornish, Y. He, and C. Paulding Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056 Sci Transl Med 3 2011 64ra61
64. Roche reports clinical trial negative results: FRAXA, http://www.fraxa.org/roche-reports-clinical-trial-negative-results/.
65. Novartis Discontinues Development of mavoglurant (AFQ056) for Fragile X Syndrome: FRAXA, http://www.fraxa.org/novartis-discontinues-development-mavoglurant-afq056-fragile-x-syndrome/.
66. M.M. Mazzocco Advances in research on the fragile X syndrome Ment Retard Dev Disabil Res Rev 6 2000 96 106
67. E.J. Mientjes, I. Nieuwenhuizen, L. Kirkpatrick, T. Zu, M. Hoogeveen-Westerveld, L. Severijnen, M. Rife, R. Willemsen, D.L. Nelson, and B.A. Oostra The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo Neurobiol Dis 21 2006 549 555
68. J.R. Brouwer, K. Huizer, L.A. Severijnen, R.K. Hukema, R.F. Berman, B.A. Oostra, and R. Willemsen CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome J Neurochem 107 2008 1671 1682
69. S.M. Hamilton, J.R. Green, S. Veeraragavan, L. Yuva, A. McCoy, Y. Wu, J. Warren, L. Little, D. Ji, and X. Cui Fmr1 and Nlgn3 knockout rats: novel tools for investigating autism spectrum disorders Behav Neurosci 128 2014 103 109
70. E.J. Nestler, and S.E. Hyman Animal models of neuropsychiatric disorders Nat Neurosci 13 2010 1161 1169
71. W. Spooren, L. Lindemann, A. Ghosh, and L. Santarelli Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders Trends Pharmacol Sci 33 2012 669 684
72. C. Henderson, L. Wijetunge, M.N. Kinoshita, M. Shumway, R.S. Hammond, F.R. Postma, C. Brynczka, R. Rush, A. Thomas, and R. Paylor Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen Sci Transl Med 4 2012 152ra128
73. Z. Liu, and C.B. Smith Lithium: a promising treatment for fragile X syndrome ACS Chem Neurosci 5 2014 477 483
74. B.M. Dolan, S.G. Duron, D.A. Campbell, B. Vollrath, B.S. Shankaranarayana Rao, H.Y. Ko, G.G. Lin, A. Govindarajan, S.Y. Choi, and S. Tonegawa Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486 Proc Natl Acad Sci U S A 110 2013 5671 5676
75. S.M. Goebel-Goody, E.D. Wilson-Wallis, S. Royston, S.M. Tagliatela, J.R. Naegele, and P.J. Lombroso Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model Genes Brain Behav 11 2012 586 600
76. T.V. Bilousova, L. Dansie, M. Ngo, J. Aye, J.R. Charles, D.W. Ethell, and I.M. Ethell Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile x mouse model J Med Genet 46 2009 94 102
77. H. Sidhu, L.E. Dansie, P.W. Hickmott, D.W. Ethell, and I.M. Ethell Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model J Neurosci 34 2014 9867 9879
78. E.K. Osterweil, S.C. Chuang, A.A. Chubykin, M. Sidorov, R. Bianchi, R.K. Wong, and M.F. Bear Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome Neuron 77 2013 243 250
79. E. Berry-Kravis, A. Knox, and C. Hervey Targeted treatments for fragile X syndrome J Neurodev Disord 3 2011 193 210
80. E. Berry-Kravis Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome Pediatr Neurol 50 2014 297 302
81. M. Hawkins, J. Boyle, K.E. Wright, R. Elles, S.C. Ramsden, A. O'Grady, M. Sweeney, D.E. Barton, T. Burgess, and M. Moore Preparation and validation of the first WHO international genetic reference panel for Fragile X syndrome Eur J Hum Genet 19 2011 10 17
82. S. Jacquemont, R.J. Hagerman, P.J. Hagerman, and M.A. Leehey Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1 Lancet Neurol 6 2007 45 55
83. B.R. Migeon The role of X inactivation and cellular mosaicism in women's health and sex-specific diseases JAMA 295 2006 1428 1433